华法林**药物基因检测报告**


|  |  |  |  |
| --- | --- | --- | --- |
| 受检者：{{zk\_name}} | 性别：{{gender}} | 年龄：{{age}} | 样本类型：{{sample\_type}} |
| 送检单位：{{hospital}} | | | 样本编号：{{zk\_id}} |
| 送检科室：{{send\_department}} | | | 送检医生：{{doc}} |
| 检测项目：华法林药物基因检测 | | | 委托日期：/ |
| 检测方法：Sanger测序 | | | 接收日期：{{zk\_accept\_time}} |
| 临床诊断：{{clinical\_diagnosis}} | | | 报告日期：{{zk\_report\_time}} |



|  |  |  |  |
| --- | --- | --- | --- |
| **检测结果总结** | | | |
| 中科基因LOGO2基因 | 检测内容 | 检测结果 | 相关说明 |
| CYP2C9 | CYP2C9\*2,  CYP2C9\*3, | {{CYP2C9}} | {{note}} |
| VKORC1 | c.-1639 | {{VKORC1}} |
| **声明：**本报告内容仅供临床参考，不能作为制定、修改、调整用药方案的唯一依据，具体剂量须结合临床。  **备注：**   |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | **{{form11}}** | **{{form12}}** | **{{form13}}** | **{{form14}}** | **{{form15}}** | **{{form16}}** | **{{form17}}** | | {{form21}} | {{form22}} | {{form23}} | {{form24}} | {{form25}} | {{form26}} | {{form27}} | | {{form31}} | {{form32}} | {{form33}} | {{form34}} | {{form35}} | {{form36}} | {{form37}} | | {{form41}} | {{form42}} | {{form43}} | {{form44}} | {{form45}} | {{form46}} | {{form47}} | | | | | |
|  | | | | |



 报 告 人：

审 核 人：

批 准 人：

**附录1：参考文献**

1. Johnson J A, Gong L, Whirlcarrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing[J]. Clinical Pharmacology & Therapeutics, 2011, 90(4):625-629.
2. Johnson J A, Caudle K E, Gong L, et al. Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update[J]. Clinical Pharmacology & Therapeutics, 2017.
3. 周宏灏，陈小平等。药物代谢酶和药物作用靶点基因检测技术指南(试行)。卫生计生委个体化医学检测技术专家委员会. 2015.
4. 谭胜蓝. 影响中国人华法林稳定剂量的遗传药理学研究[D]. 中南大学, 2012.

**附录2：Sanger测序结果峰图**

|  |  |
| --- | --- |
| **CYP2C9\*2** | **CYP2C9\*3** |
| {{peak\_figure\_CYP2C9\_2}} | {{peak\_figure\_CYP2C9\_3}} |
| **VKORC1:** **c.-1639** |
| {{peak\_figure\_VKORC1}} |